NIMH Pages about Alzheimer's Disease
Clinical Trials Page
Find current studies on Alzheimer's Disease…
Science News
- Use of Antipsychotics in Alzheimer’s Patients May Lead to Detrimental Metabolic Changes
- April 15, 2009 • Science Update
Atypical antipsychotic medications are associated with weight gain and other metabolic changes among patients with Alzheimer’s disease, according to a recent analysis of data from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness—Alzheimer’s Disease (CATIE-AD) study. The study was published online ahead of print April 15, 2009, in the American Journal of Psychiatry. - Antipsychotic Medications May Ease Some Alzheimer’s Symptoms, Not Others
- June 23, 2008 • Science Update
Antipsychotic medications may lessen symptoms like hostility and aggression in patients with Alzheimer’s disease, but do not appear to lessen other symptoms or improve quality of life, according to a recent analysis of data from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer’s Disease (CATIE-AD) study. - Cortex Area Thinner in Youth with Alzheimer’s-Related Gene
- April 24, 2007 • Press Release
A part of the brain first affected by Alzheimer’s disease is thinner in youth with a risk gene for the disorder, a brain imaging study by researchers at the National Institute of Mental Health (NIMH), one of the National Institutes of Health (NIH), has found. - Antipsychotic Medications Used to Treat Alzheimer’s Patients Found Lacking
- October 11, 2006 • Press Release
Commonly prescribed antipsychotic medications used to treat Alzheimer’s patients with delusions, aggression, hallucinations, and other similar symptoms can benefit some patients, but they appear to be no more effective than a placebo when adverse side effects are considered, according to the first phase of a large-scale clinical trial funded by NIMH. - Lithium Shows Promise Against Alzheimer’s in Mouse Model
- May 21, 2003 • Press Release
An enzyme crucial to formation of Alzheimer’s plaques and tangles may hold promise as a target for future medications, suggest studies in mice and cells.
Director’s Updates
- NIMH Perspective on Treating Alzheimer’s Patients with Antipsychotic Medications
- October 12, 2006
The recent publication of phase 1 results from the NIMH-funded Clinical Antipsychotic Trials in Intervention Effectiveness for Alzheimer's disease (CATIE-AD) in the New England Journal of Medicine provides new information about the use of several "atypical" antipsychotic medications for the treatment of psychotic symptoms in patients with Alzheimer's disease.
